Barclays’s Nuvation Bio NUVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.72M Buy
664,537
+432,743
+187% +$2.71M ﹤0.01% 2200
2026
Q2
$1.32M Buy
231,794
+117,303
+102% +$573K ﹤0.01% 2630
2026
Q1
$491K Sell
114,491
-324,781
-74% -$1.81M ﹤0.01% 3198
2025
Q4
$3.94M Sell
439,272
-56,662
-11% -$351K ﹤0.01% 2406
2025
Q3
$1.83M Sell
495,934
-523,631
-51% -$1.43M ﹤0.01% 2948
2025
Q2
$1.99M Sell
1,019,565
-330,198
-24% -$688K ﹤0.01% 2849
2025
Q1
$2.38M Buy
1,349,763
+70,051
+5% +$159K ﹤0.01% 2499
2024
Q4
$3.4M Buy
1,279,712
+61,391
+5% +$158K ﹤0.01% 2475
2024
Q3
$2.79M Sell
1,218,321
-333,817
-22% -$1.02M ﹤0.01% 2579
2024
Q2
$4.53M Sell
1,552,138
-53,568
-3% -$163K ﹤0.01% 1607
2024
Q1
$5.84M Buy
1,605,706
+1,118,954
+230% +$2.15M ﹤0.01% 1748
2023
Q4
$735K Buy
486,752
+384,443
+376% +$495K ﹤0.01% 3650
2023
Q3
$137K Sell
102,309
-2,845
-3% -$4.74K ﹤0.01% 3468
2023
Q2
$189K Sell
105,154
-119,324
-53% -$203K ﹤0.01% 3273
2023
Q1
$373K Buy
224,478
+156,016
+228% +$316K ﹤0.01% 3462
2022
Q4
$131K Buy
68,462
+11,909
+21% +$24.1K ﹤0.01% 4068
2022
Q3
$127K Buy
56,553
+3,377
+6% +$9.6K ﹤0.01% 3427
2022
Q2
$172K Sell
53,176
-7,746
-13% -$33.8K ﹤0.01% 3521
2022
Q1
$321K Buy
+60,922
New +$342K ﹤0.01% 3172

Other funds holding NUVB

Barclays's NUVB Position: Q3 2026 in Review

Barclays increased its Nuvation Bio (NUVB) stake by 187% in Q3 2026, buying an estimated $2.71M and bringing the position to 664,537 shares worth $3.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2200.

Barclays first reported a position in NUVB in Q1 2022 and has held it in 19 quarters since. The position peaked at $5.84M in Q1 2024. 196 funds tracked by Wall St. Rank hold NUVB as of Q3 2026.

  • Barclays held 664,537 shares of Nuvation Bio worth $3.72M as of Q3 2026.
  • Barclays bought 432,743 Nuvation Bio shares in Q3 2026, an estimated $2.71M.
  • Nuvation Bio made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2200 holding.
  • Barclays first reported a position in Nuvation Bio in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Nuvation Bio position peaked at $5.84M in Q1 2024.
  • 196 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.